Healthcare
Century Therapeutics, Inc.(IPSC)
Live Price
Offline$2.17
+2.36% today
1Y Change
+306.36%
Window
Jun 25, 2025 โ Jun 22, 2026
- Market Cap
- $200.00M
- Revenue Growth
- +1556.8%
- EPS Growth
- +93.2%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 25, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Century Therapeutics, Inc. (IPSC) is a Healthcare stock with a market cap of $200.00M and listed on NASDAQ. The stock last traded around $2.17 and up 306.4% across the available one-year price window (Jun 25, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of +1556.8%, EPS growth of +93.2%, a dividend yield of 0.0%. What stands out right now is revenue +1556.8%, EPS +93.2%, free cash flow +5.0% with operating margin -13.8% and ROIC -7.2%. Valuation is more restrained than many high-expectation growth names at price/sales 1.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines IPSC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+1556.8% vs +7.6% peer median
Operating Margin
Below sector median
-13.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +1556.8% and EPS at +93.2%, with operating margin around -13.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.4% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | โ | -0.4% | +7.9% | +1.3% |
2026 Mar 12, 2026 | +10.7% | -6.4% | -0.4% | -10.0% |
2025 Nov 13, 2025 | +17.9% | +1.5% | +5.6% | +20.0% |
Benchmark Edge
IPSC vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IPSC
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IPSC Max Drawdown
-36.98%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IPSC and SPY.
Company Overview
Century Therapeutics, Inc.
NASDAQ Global Select
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
- Leadership
- Brent Pfeiffenberger
- IPO Date
- Jun 18, 2021
- Employees
- 140
- Street Address
- 3675 Market Street
- Mailing
- Philadelphia, PA, 19104
- Region
- Philadelphia, PA, US
- Reporting Currency
- USD
- Investor Line
- 267 817 5790
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.8
- Price/Book
- 1.2
Growth
- Revenue
- +1556.8%
- EPS
- +93.2%
- Free Cash Flow
- +5.0%
Profitability
- Gross Margin
- 90.9%
- Operating Margin
- -13.8%
- Net Margin
- -8.8%
- ROE
- -4.9%
- ROIC
- -7.2%
Balance Sheet
- Debt/Equity
- 0.27
- Current Ratio
- 5.97
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.